Some Biomarkers in Bronchial Asthma in Children

NCT04175093 | Unknown

• 1 other identifier: BRASTHMA
• Study Type: observational
• Target: 105
• Locations: 0 countries
• Sites: N/A

Brief Summary

Asthma, a disease characterized by chronic airway inflammation and hyper -responsiveness, is a common disease that affects all age groups. Asthma may be manifested as irreversible airflow obstruction in some patients. Although the pathogenesis of asthma is not well understood, increased oxidative stress due to an imbalance of oxidants and antioxidants has been found to be associated with asthma. In asthma, inflammation-related oxidative stress is driven by exposure to a variety of triggers, including allergens and viruses, which activate components of both the innate and acquired immune responses. Protection by escaping from triggering factors or standardization of asthma medication is difficult and usually is not enough for effective treatment. On the other hand, correction of antioxidative systems may be more efficacious in the control of asthmatic inflammation and asthma symptoms. Little is known about the role of asymmetric dimethylarginine in the pathogenesis of asthmatic airway inflammation. The lung is a major source of asymmetric dimethylarginine that can promote oxidative stress by a reduction in nitric oxide synthesis which would result in higher levels of peroxynitrite, that causes oxidative cell damage, and exacerbate airway inflammation. asymmetric dimethylarginine can modify lung function, increase airway hyper-reactivity even in non-inflamed airways, and promote lung collagen production and deposition. Increased asymmetric dimethylarginine in serum has been found to be associated with the severity of symptoms of asthma in obese adults. Malondialdehyde is an oxidant marker of pulmonary oxidative stress, and lipid peroxidation. Paraoxonase, an antioxidant enzyme may play a protective role in asthma. It hydrolyzes lipid peroxides and prevents low-density lipoprotein oxidation.

Conditions

Bronchial Asthma

Outcome Measures

Primary Outcomes (1)

• The percentage of asymmetric dimethylarginine in the study groups

  measurement from serum samples by competitive ELISA with a standard range from 0.1 to 5.0 μmol/L.

  24 hours

Study Arms (3)

Mild persistent asthma

• Group I, patients with mild persistent asthma.

Diagnostic Test: asymmetric dimethylarginine

Moderate persistent asthma

• Group II, patients with moderate persistent asthma.

Diagnostic Test: asymmetric dimethylarginine

Severe persistent asthma

• Group III ,patients with severe persistent asthma.

Diagnostic Test: asymmetric dimethylarginine

Interventions

asymmetric dimethylarginine DIAGNOSTIC_TEST

measurement by ELISA of asymmetric dimethylarginine

Mild persistent asthma; Moderate persistent asthma; Severe persistent asthma

Eligibility Criteria

• Age: 3 Years - 12 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Probability Sample

Study Population

All the children included in the study will be exposed to full clinical examination and history for assessment of severity of asthma in patient groups according to the guidelines for diagnosis and managemt of asthma 2007.

You may not qualify if:

• Obese children,
• The presence of chronic heart, liver and kidney diseases, concomitant chronic inflammatory disease and autoimmune disorders, and Diabetes mellitus.
• Patients taking antioxidant drugs, vitamins, diuretics, hormone replacement therapy will be also excluded.
• Children aged less than six years. 5-children who have symptoms of lower or upper respiratory tract infection or asthma exacerbation within the previous four weeks.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: November 20, 2019
• First Posted: November 22, 2019
• Study Start: November 29, 2019
• Primary Completion: November 21, 2020
• Study Completion: November 21, 2021
• Last Updated: November 25, 2019

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will not share